FindTrial
Sign In

A study to compare the benefits between itraconazole and terbinafine with itraconazole in skin fungal infections

A prospective, randomized, open label, comparative study of efficacy & tolerability of oral itraconazole versus combination therapy with oral itraconazole & oral terbinafine in treatment of dermatophytosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/047904
Enrollment
150
Registered
2022-12-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B359- Dermatophytosis, unspecified

Interventions

Intervention1: Oral Itraconazole: Oral Itraconazole 100 mg twice daily for 3 weeks Intervention2: Oral itraconazole: Oral itraconazole 100 mg twice daily for 3 weeks Control Intervention1: Oral itraco

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects aged between 18-65 years of age with clinical diagnosis of dermatophytosis(tinea corporis,tinea faciei,tinea cruris) including all new cases & recurrent cases of dermatophytosis

Exclusion criteria

Exclusion criteria: Pregnant & lactating women Subjects with history of preexisting liver & renal disease Subjects with history of HIV or under antiretroviral therapy Subjects with history of hypersensitivity to the drugs under study Subjects under immunosuppressive therapy

Design outcomes

Primary

MeasureTime frame
Itching Erythema Scaling Timepoint: At baseline,3,6 and 9 weeks—

Secondary

MeasureTime frame
Any side effects like GI disturbances, headache, rashes, allergic symptoms Timepoint: 0,3,6 and 9 weeks—

Countries

India

Contacts

Public ContactSrinjoy Bhattacharya

Kempegowda Institute of Medical Sciences

drgirish_k@rediffmail.com9980911060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026